# Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06759090/  
OnCo record `nct06759090` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab in pancreatic cancer, run by Zhejiang University, not yet recruiting.

## Summary

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06759090 by Zhejiang University, with a registry enrolment figure of 43 participants, started 2025-01-15 and due to reach its primary completion in 2027-01-15. Interventions recorded: Metronomic capecitabine; Camrelizumab; Apatinib Mesylate Tablets. Conditions listed: Metastatic Pancreatic Carcinoma. Primary outcome: Objective Response Rate (ORR); Disease Control Rate (DCR); Safety of treatment. Pancreatic eligibility wording from the registry: "* 1: Age is 18 years or older; 2: Pathologically confirmed pancreatic adenocarcinoma; 3: As determined by the investigator, second-line treatment for advanced pancreatic cancer has failed; or the patient has a poor performance status (PS score \>1), and the investigator considers that the patient ca". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06759090
- Phase: 2
- Setting: Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate in Advanced Pancreatic Cancer：A Multi-center, Single-arm, Phase II Exploratory Trial
- Sponsor: Zhejiang University
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT06759090: https://clinicaltrials.gov/study/NCT06759090

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06759090.json